Middle East And Africa Drug Delivery Devices Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2031 |
 Marktgröße (Basisjahr) | USD 26.41 Billion |
 Marktgröße (Prognosejahr) | USD 48.96 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Markt für Geräte zur Arzneimittelverabreichung im Nahen Osten und in Afrika, nach Produkttyp ( orale Arzneimittelverabreichunginjizierbare Arzneimittelverabreichung , topische Arzneimittelverabreichung, okuläre Arzneimittelverabreichung, nasale Arzneimittelverabreichungpulmonale Arzneimittelverabreichung , transmukosale Arzneimittelverabreichung und implantierbare Arzneimittelverabreichung ), Endverbraucher (Krankenhäuser, häusliche Gesundheitspflege, Kliniken, gemeinschaftliche Gesundheitspflege und andere), Vertriebskanal (direkte Ausschreibungen, Krankenhausapotheken, Apothekenläden und Online-Apotheken) – Branchentrends und Prognose bis 2031.
Marktanalyse und -größe für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika
Der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika verzeichnet ein starkes Wachstum, das durch die steigende Prävalenz chronischer und nicht chronischer Krankheiten, das Wachstum bei der Entwicklung von Geräten für Biologika und das zunehmende Bewusstsein für Diagnose und Behandlung angetrieben wird. Der Markt ist durch die Präsenz einer großen Anzahl von Akteuren gekennzeichnet, die eine breite Palette von Diagnosegeräten anbieten, die auf die vielfältigen Bedürfnisse der Gesundheitsdienstleister in der Region zugeschnitten sind.
Data Bridge Market Research analysiert, dass der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika im Prognosezeitraum von 2024 bis 2031 mit einer durchschnittlichen jährlichen Wachstumsrate von 8,3 % wächst und von 26,41 Milliarden US-Dollar im Jahr 2023 auf 48,96 Milliarden US-Dollar im Jahr 2031 ansteigen dürfte.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2024 bis 2031 |
|
Basisjahr |
2023 |
|
Historisches Jahr |
2022 (Anpassbar 2016–2021) |
|
Quantitative Einheiten |
Umsatz in Milliarden USD |
|
Abgedeckte Segmente |
Produkttyp (orale Arzneimittelverabreichung, injizierbare Arzneimittelverabreichung, topische Arzneimittelverabreichung, ophthalmische Arzneimittelverabreichung, nasale Arzneimittelverabreichung, pulmonale Arzneimittelverabreichung, transmukosale Arzneimittelverabreichung und implantierbare Arzneimittelverabreichung), Endverbraucher (Krankenhäuser, häusliche Gesundheitspflege , Kliniken, kommunale Gesundheitspflege und andere), Vertriebskanal (Direktausschreibungen, Krankenhausapotheken, Apothekenläden und Online-Apotheken) |
|
Abgedeckte Länder |
Südafrika, Ägypten, Saudi-Arabien, Vereinigte Arabische Emirate, Israel und der Rest des Nahen Ostens und Afrikas |
|
Abgedeckte Marktteilnehmer |
Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Merck & Co., Inc., Sanofi, West Pharmaceutical Services Inc. unter anderem |
Marktdefinition
Arzneimittelverabreichungsgeräte sind medizinische Geräte, die Medikamente kontrolliert und gezielt in den Körper abgeben und so ihre Wirksamkeit, Sicherheit und Patienten-Compliance verbessern. Diese Geräte können extern (z. B. Inhalatoren, Injektoren und Pumpen) oder intern (z. B. implantierbare Geräte) sein und werden zur Verabreichung einer breiten Palette von Medikamenten verwendet, darunter kleine Moleküle, Biologika und Impfstoffe. Sie können die Freisetzungsrate, Bioverfügbarkeit und Absorption von Medikamenten verändern und Patienten und Gesundheitsdienstleistern eine Echtzeitüberwachung und Rückmeldung bieten. Arzneimittelverabreichungsgeräte spielen eine entscheidende Rolle bei der Optimierung von Behandlungsergebnissen und der Verbesserung der Lebensqualität von Patienten bei verschiedenen Krankheiten und Beschwerden, darunter chronische Krankheiten, Infektionskrankheiten und Krebs.
Marktdynamik für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Steigende Prävalenz chronischer und nicht chronischer Krankheiten
Die Prävalenz von Krankheiten und Leiden wie Herz-Kreislauf-Erkrankungen (CVDs), Asthma, Krebs, neurologischen Störungen, Schlaganfällen, Diabetes und Atemwegserkrankungen hat im Laufe der Zeit deutlich zugenommen. Im Folgenden sind einige wichtige Statistiken zu einigen der chronischen Krankheiten aufgeführt. Die steigende Prävalenz chronischer und nicht chronischer Krankheiten beeinflusst das Wachstum des Marktes für Arzneimittelverabreichungsgeräte erheblich. Chronische Krankheiten wie Diabetes, Herz-Kreislauf-Erkrankungen und Atemwegserkrankungen breiten sich immer weiter aus und erfordern langfristige Behandlungspläne, die effiziente und zuverlässige Methoden zur Arzneimittelverabreichung erfordern.
- Wachstum in der Entwicklung von Geräten für biologische Arzneimittel
Biologika gelten als eines der am schnellsten wachsenden Segmente auf dem Pharmamarkt. Die Entwicklung und Herstellung von Biologika für Marken- und Generikamedikamente wird durch die Präsenz neuer Akteure immer wettbewerbsintensiver. Biologika werden im Allgemeinen durch Injektionen in Arme, Beine oder Bauch verabreicht. Beispiele hierfür sind Cimzia, Cosentyx, Enbrel und Humira.
Gelegenheit
- Steigende Akzeptanz von Medikamenten-Selbstverabreichungsgeräten
Die Selbstverabreichung von Medikamenten durch Patienten dürfte den Akteuren im Arzneimittelverabreichungsbereich, die sich auf die Entwicklung innovativer und neuer Geräte konzentrieren, erhebliche Wachstumschancen bieten. Ein wichtiger Faktor hierfür ist die wachsende ältere Bevölkerung, da diese eine große Verbraucherbasis für Geräte zur Verabreichung von Medikamenten für die häusliche Pflege bildet. Pharmaunternehmen konzentrieren sich auf die Entwicklung patientenfreundlicher Therapien und Kombinationsprodukte aus Medikamenten und Geräten zur Selbstverabreichung. Mit der zunehmenden Akzeptanz der Selbstverabreichung steigt auch der Bedarf an anwendungsspezifischen Arzneimitteln zur Injektion, Inhalation, topischen und transdermalen Verabreichung.
Einschränkung/Herausforderung
- Nebenwirkungen von Arzneimittelabgabesystemen
Unerwünschte Reaktionen auf Arzneimittelverabreichungssysteme können zu einer geringeren Patientencompliance führen, was wiederum eine geringere Nachfrage nach dem Gerät zur Folge haben kann. Dies kann sich negativ auf den Umsatz und den Ertrag des Geräteherstellers auswirken. Nebenwirkungen können Bedenken hinsichtlich der Patientensicherheit aufkommen lassen, was zu verstärkter Kontrolle und Regulierung durch die Aufsichtsbehörden führt. Dies kann zu Verzögerungen bei der Produkteinführung, zusätzlichen Testanforderungen und höheren Kosten für die Gerätehersteller führen. Darüber hinaus können Nebenwirkungen dazu führen, dass Patienten das Gerät ablehnen, was wiederum eine geringere Nachfrage nach dem Gerät zur Folge hat. Dies kann insbesondere bei Geräten problematisch sein, die eine langfristige Verwendung erfordern, wie z. B. implantierbare Geräte.
Jüngste Entwicklungen
- Im August 2023 reichte Janssen Pharmaceutical Companies von Johnson & Johnson Services, Inc. den ergänzenden Biologics License Application (sBLA) bei der US-amerikanischen Food and Drug Administration (FDA) ein und beantragte die Zulassung von DARZALEX in Kombination mit Kyprolis und Dexamethason zur Behandlung von rezidiviertem/refraktärem multiplem Myelom. Im Falle einer Genehmigung wird dies das Produktportfolio und auch die Umsatzgenerierung des Unternehmens erweitern
- Im Januar 2020 gaben die Janssen Pharmaceutical Companies von Johnson & Johnson Services, Inc. bekannt, dass die EU die Genehmigung zur Vermarktung von Erleada erteilt hat. Das Produkt wird zur Behandlung von metastasiertem hormonsensitivem Prostatakrebs (mHSPC) in Kombination mit der Androgenentzugstherapie (ADT) eingesetzt. Dies wird ihre Marktpräsenz erhöhen und die Umsatzgenerierung weiter steigern.
- Im Dezember 2020 gaben die Janssen Pharmaceutical Companies von Johnson & Johnson Services, Inc. die EG-Zulassung des Nasensprays SPRAVATO bekannt, das ihr Produktportfolio erweitern und den Umsatz weiter steigern wird.
Marktumfang für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika
Der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und Afrika ist in drei wichtige Segmente unterteilt, basierend auf Produkttyp, Endbenutzer und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen dabei, Nischenwachstumsbereiche und Strategien zur Marktbearbeitung zu analysieren und Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten zu bestimmen.
Produkttyp
- Orale Arzneimittelverabreichung
- Injizierbare Arzneimittelverabreichung
- Topische Arzneimittelverabreichung
- Ophthalmische Arzneimittelverabreichung
- Nasale Arzneimittelverabreichung
- Pulmonale Arzneimittelverabreichung
- Transmukosale Arzneimittelverabreichung
- Implantierbare Arzneimittelverabreichung
Auf der Grundlage des Produkttyps ist der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika in die folgenden Segmente unterteilt: injizierbare Arzneimittelverabreichungsformulierungen, injizierbare Arzneimittelverabreichung, topische Arzneimittelverabreichung, ophthalmische Arzneimittelverabreichung, nasale Arzneimittelverabreichung, pulmonale Arzneimittelverabreichung, transmukosale Arzneimittelverabreichung und implantierbare Arzneimittelverabreichung.
Endbenutzer
- Krankenhäuser
- Häusliche Gesundheitspflege
- Kliniken
- Gesundheitsfürsorge in der Gemeinde
- Sonstiges
Auf der Grundlage des Endverbrauchers ist der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika in Krankenhäuser, häusliche Gesundheitspflege, Kliniken, kommunale Gesundheitspflege und andere unterteilt.
Vertriebskanal
- Direkte Ausschreibungen
- Krankenhausapotheken
- Apotheken
- Online-Apotheke
Auf der Grundlage der Vertriebskanäle ist der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika in Direktausschreibungen, Krankenhausapotheken, Apothekenläden und Online-Apotheken segmentiert.
Regionale Analyse/Einblicke zum Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika
Der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika wird analysiert und Einblicke in die Marktgröße und Trends werden basierend auf Produkttyp, Endbenutzer und Vertriebskanal, wie oben angegeben, bereitgestellt.
Die in diesem Marktbericht abgedeckten Länder sind Südafrika, Saudi-Arabien, die Vereinigten Arabischen Emirate, Ägypten, Israel und der Rest des Nahen Ostens und Afrikas.
Südafrika dürfte den Markt im Nahen Osten und in Afrika dominieren, da sein Gesundheitssektor rasch wächst, erhebliche Investitionen in Innovationen im Bereich der Medizintechnik getätigt werden und eine große und zunehmend wohlhabende Bevölkerung den Bedarf nach fortschrittlichen Gesundheitslösungen antreibt.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die die aktuellen und zukünftigen Trends des Marktes beeinflussen. Datenpunkte wie Downstream- und Upstream-Wertschöpfungskettenanalysen, technische Trends und Porters Fünf-Kräfte-Analyse sowie Fallstudien sind einige der Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.
Wettbewerbsumfeld und Marktanteilsanalyse für Arzneimittelverabreichungsgeräte im Nahen Osten und Afrika
Der Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika ist basierend auf Produkttyp, Endbenutzer und Vertriebskanal in drei wichtige Segmente unterteilt.
Die Wettbewerbslandschaft des Marktes für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika bietet Details nach Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika.
Zu den wichtigsten Akteuren auf dem Markt für Arzneimittelverabreichungsgeräte im Nahen Osten und in Afrika zählen unter anderem Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Merck & Co., Inc., Sanofi und West Pharmaceutical Services Inc.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
6.2.2 HIGH COSTS OF INJECTABLE DRUGS
6.2.3 STRINGENT REGULATORY SCENARIO
6.3 OPPORTUNITIES
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY
7 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 ORAL DRUG DELIVERY
7.2.1 SOLID ORAL DRUGS
7.2.1.1 TABLETS
7.2.1.2 CAPSULES
7.2.1.3 PILLS
7.2.1.4 POWDERS
7.2.2 LIQUID ORAL DRUGS
7.2.2.1 SYRUPS
7.2.2.2 SOLUTIONS
7.2.3 SEMI SOLID ORAL DRUGS
7.2.3.1 GELS
7.2.3.2 EMULSIONS
7.2.3.3 ELIXIRS
7.3 INJECTABLE DRUG DELIVERY
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS
7.3.1.3 LONG ACTING INJECTION FORMULATIONS
7.3.2 INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1.1 BY MATERIAL
7.3.2.1.1.1 GLASS
7.3.2.1.1.2 PLASTIC
7.3.2.1.2 BY PRODUCT TYPE
7.3.2.1.2.1 FILLABLE
7.3.2.1.2.2 PRE-FILLED
7.3.2.1.3 BY USABILITY
7.3.2.1.3.1 REUSABLE SYRINGES
7.3.2.1.3.2 DISPOSABLE SYRINGES
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES
7.3.2.2.1 NEEDLE FREE INJECTORS
7.3.2.2.2 WEARABLE INJECTORS
7.3.2.2.3 PEN INJECTOR
7.3.2.2.4 AUTO INJECTORS
7.3.2.2.5 OTHERS
7.4 TOPICAL DRUG DELIVERY
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.1.1 OINTMENTS
7.4.1.1.2 CREAMS
7.4.1.1.3 LOTIONS
7.4.1.1.4 GELS
7.4.1.1.5 PASTES
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.2.1 SUSPENSIONS
7.4.1.2.2 SOLUTIONS
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.3.1 POWDER
7.4.1.3.2 SUPPOSITORS
7.5 OPHTHALMIC DRUG DELIVERY
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1.1 SOLUTIONS
7.5.1.1.2 SUSPENSIONS
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.2.1 GELS
7.5.1.2.2 OINTMENTS
7.5.2 OCCULAR DRUG DELIVERY DEVICES
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DROPS
7.6.2 NASAL SPRAYS
7.6.3 NASAL POWDERS
7.6.4 NASAL GELS
7.7 PULMONARY DRUG DELIVERY
7.7.1 METERED DOSE INHALERS (MDI)
7.7.2 DRY POWDER INHALERS (DPI)
7.7.3 NEBULIZERS
7.7.3.1 JET NEBULIZERS
7.7.3.2 ULTRASONIC NEBULIZERS
7.7.3.3 SOFT MIST NEBULIZERS
7.8 TRANSMUCOSAL DRUG DELIVERY
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
7.8.1.1 BUCCAL DRUG DELIVERY
7.8.1.2 SUBLINGUAL DRUG DELIVERY
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
7.9 IMPLANTABLE DRUG DELIVERY
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
8 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 HOME HEALTHCARE
8.4 CLINICS
8.5 COMMUNITY HEALTHCARE
8.6 OTHERS
9 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 HOSPITAL PHARMACIES
9.4 PHARMACY STORES
9.5 ONLINE PHARMACY
10 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
10.1.1 SOUTH AFRICA
10.1.2 SAUDI ARABIA
10.1.3 U.A.E.
10.1.4 EGYPT
10.1.5 ISRAEL
10.1.6 REST OF MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NOVARTIS AG
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 F. HOFFMANN-LA ROCHE LTD
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BAYER AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.5 PFIZER INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENT
13.6 3M
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 ABBVIE INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 BD
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.1 ELCAM MEDICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ENABLE INJECTIONS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 GERRESHEIMER AG
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
13.13 GSK PLC.
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENTS
13.14 INSULET CORPORATION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 MEDMIX
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENTS
13.16 MERCK & CO., INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 ORASURE TECHNOLOGIES INC.
13.17.1 COMPANY SNAPSHOT
13.17.2 REVENUE ANALYSIS
13.17.3 PRODUCT PORTFOLIO
13.17.4 RECENT DEVELOPMENT
13.18 SANOFI
13.18.1 COMPANY SNAPSHOT
13.18.2 REVENUE ANALYSIS
13.18.3 PRODUCT PORTFOLIO
13.18.4 RECENT DEVELOPMENTS
13.19 SMC LTD.
13.19.1 COMPANY SNAPSHOT
13.19.2 REVENUE ANALYSIS
13.19.3 PRODUCT PORTFOLIO
13.19.4 RECENT DEVELOPMENTS
13.2 VIVO SMART MEDICAL DEVICES LTD.
13.20.1 COMPANY SNAPSHOT
13.20.2 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 WEST PHARMACEUTICAL SERVICES, INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022
TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 82 SOUTH AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 83 SOUTH AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 84 SOUTH AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 85 SOUTH AFRICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 86 SOUTH AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 87 SOUTH AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 88 SOUTH AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 89 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 90 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 92 SOUTH AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 93 SOUTH AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 SOUTH AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 95 SOUTH AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 SOUTH AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 SOUTH AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 SOUTH AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 99 SOUTH AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 100 SOUTH AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 SOUTH AFRICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 SOUTH AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 107 SOUTH AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 108 SOUTH AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 110 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 111 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 112 SAUDI ARABIA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 113 SAUDI ARABIA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 SAUDI ARABIA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 SAUDI ARABIA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 SAUDI ARABIA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 SAUDI ARABIA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 SAUDI ARABIA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 119 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 120 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 121 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 122 SAUDI ARABIA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 123 SAUDI ARABIA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 124 SAUDI ARABIA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 125 SAUDI ARABIA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 SAUDI ARABIA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 SAUDI ARABIA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SAUDI ARABIA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 129 SAUDI ARABIA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 130 SAUDI ARABIA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SAUDI ARABIA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 SAUDI ARABIA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 133 SAUDI ARABIA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 134 SAUDI ARABIA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 SAUDI ARABIA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 SAUDI ARABIA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 SAUDI ARABIA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 SAUDI ARABIA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 140 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 141 U.A.E. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 142 U.A.E. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 143 U.A.E. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 144 U.A.E. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 145 U.A.E. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 146 U.A.E. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 147 U.A.E. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 148 U.A.E. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 149 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 150 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 151 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 152 U.A.E. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 153 U.A.E. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 154 U.A.E. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 155 U.A.E. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 U.A.E. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 U.A.E. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 U.A.E. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 U.A.E. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 160 U.A.E. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 U.A.E. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 U.A.E. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 163 U.A.E. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 164 U.A.E. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 165 U.A.E. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 166 U.A.E. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 167 U.A.E. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 168 U.A.E. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 169 U.A.E. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 U.A.E. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 EGYPT DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 172 EGYPT ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 173 EGYPT SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 174 EGYPT LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 175 EGYPT SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 176 EGYPT INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 177 EGYPT INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 178 EGYPT INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 179 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 180 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 181 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 182 EGYPT SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 183 EGYPT TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 184 EGYPT TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 185 EGYPT SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 EGYPT LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 EGYPT LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 EGYPT OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 189 EGYPT OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 190 EGYPT LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 EGYPT SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 EGYPT NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 193 EGYPT PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 194 EGYPT NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 195 EGYPT TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 196 EGYPT ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 197 EGYPT OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 198 EGYPT IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 199 EGYPT DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 200 EGYPT DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 201 ISRAEL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 202 ISRAEL ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 203 ISRAEL SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 204 ISRAEL LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 205 ISRAEL SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 206 ISRAEL INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 207 ISRAEL INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 208 ISRAEL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 209 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 210 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 211 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 212 ISRAEL SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 213 ISRAEL TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 214 ISRAEL TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 215 ISRAEL SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 ISRAEL LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 ISRAEL SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 ISRAEL OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 219 ISRAEL OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 220 ISRAEL LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 ISRAEL SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 ISRAEL NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 223 ISRAEL PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 224 ISRAEL NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 225 ISRAEL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 226 ISRAEL ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 227 ISRAEL OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 228 ISRAEL IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 229 ISRAEL DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 230 ISRAEL DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 EIGHT SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031
FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET
FIGURE 17 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, 2023
FIGURE 22 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)
FIGURE 24 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SNAPSHOT (2023)
FIGURE 30 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
